Exagen (XGN) delivered a quarter that looks better at the top line than underneath it. The company reported a loss of $0.25 per share, missing the -$0.19 consensus by 31.6%. Revenue of $18.42 million edged past the $18.28 million estimate by 0.7% and grew 6.8% year over year. Management reiterated full-year revenue guidance of $72 million to $75 million, a range already raised in the second quarter. That is the central tension. Revenue is still being delivered, but almost all of the growth now comes from pricing rather than test volume, and customer acquisition has slowed sharply.

The earnings figures need some explanation. On Earnings Whispers' normalized basis, earnings fell 31.6% year over year. The GAAP release tells a different story: net loss per share narrowed to $0.25 from $0.31, and net loss fell to $6.3 million from $7.1 million. That GAAP improvement owes a lot to non-operating items. The warrant liability charge dropped to $0.9 million from $2.7 million, and interest expense eased slightly. Operating performance went the other way. Operating loss widened to $4.4 million from $3.1 million as operating expenses rose 16% to $15.2 million, against 7% revenue growth. The increase included SG&A growth of roughly $1.4 million, a $587,000 in-process R&D charge tied to the July acquisition of an AI-enabled rheumatology workflow platform, and stock-based compensation that roughly doubled to $1.2 million. Gross margin improved only modestly to 58.8% from 58.4%. Adjusted EBITDA loss was essentially flat at $1.9 million, so the quarter delivered none of the operating leverage that drove the 30%-plus year-to-date improvement.

The call made the deceleration explicit:

• **Revenue growth:** 7%, down from 12% in the first quarter and roughly 20% in fiscal 2025.
• **AVISE CTD volume:** up only 2%, compared with 10% in Q1 and 11% last year.
• **Ordering physicians:** up 5%, down from 15% in Q1.

Management attributed the slowdown to a difficult 2025 comparison and seasonality. That explanation is plausible, but the slowing physician count is harder to dismiss as a calendar quirk, and analysts openly asked whether double-digit growth can return beyond 2026.

The offset is pricing. Trailing twelve-month ASP reached $451, the 14th straight quarterly increase, up from $444 in Q1 and $441 at the end of 2025. Management now assumes mid-single-digit ASP growth for the year, up from low-single-digit earlier. The quality of that ASP deserves scrutiny, however. Aged-claim collections fell to $0.8 million from $1.3 million in Q2, and those collections are worth roughly $14 of quarterly ASP. Looking further out, PAMA could reduce the blended reimbursement rate by a low-single-digit percentage in 2027 through the generic CPT codes, although the $840 PLA code is expected to hold. Bears have legitimate ammunition: the pricing lever that is carrying growth faces a regulatory headwind just as volume is flattening.

The forward story is where management's improving tone is most credible:

• **Myositis test:** completed analytical and clinical validation, with a New York State submission expected by the end of January and launch on track for early 2027. Management now views the testing population as materially larger than the roughly 100,000 patients previously cited, with possible extension into pulmonology and interstitial lung disease.
• **Pharma services:** year-to-date revenue rose about 85% to $2.2 million, and backlog climbed to roughly $5.5 million.
• **Upcoming event:** a December 15 investor webcast should give the pipeline narrative more visibility.

The balance sheet strengthened to about $28 million in cash, pro forma roughly $33 million, from about $22 million in Q1. That improvement was funded by about $6.5 million of at-the-market equity issuance plus a $5 million debt draw, which brings dilution and leverage. Management reaffirmed its $80 million revenue run-rate breakeven target.

Investor sentiment slipped from slightly positive (0.0255) to slightly negative (-0.0260). The shift is modest, but it suggests expectations cooled heading into the print. The stock's path has been volatile:

• **Since the August report:** shares are up 23.5%, at $7.10 versus a $5.75 open.
• **Versus the 200-day average:** about 39% above it, at $5.11.
• **Within the quarter:** shares peaked at $9.22 in mid-October, then fell to a quarter low of $5.69 on November 6, just days before the report, before rebounding nearly 25%.

That round trip shows a market that has already debated the growth slowdown aggressively. The Earnings Whispers AVWAP trend remains negative even as most other trend readings sit at neutral.

The bottom line is that Exagen kept its revenue promise but missed on earnings and showed a business whose volume engine has slowed to a crawl. Pricing gains, pharma services and an early-2027 myositis launch give the company a credible path to its breakeven target. Until volume and physician growth reaccelerate, however, the investment case rests more on pipeline execution and reimbursement durability than on the core test's momentum.